• C Kawanishi, T Hanihara, Y Shimoda, K Suzuki, N Sugiyama, H Onishi, T Miyakawa, Y Yamada, and K Kosaka.
• Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan.
• Am J Psychiatry. 1998 Sep 1; 155 (9): 1275-7.

ObjectiveThe molecular basis of neuroleptic malignant syndrome is unclear, but studies suggest that genetic factors are involved in its pathogenesis. Considering possible involvement of the serotonergic system in neuroleptic malignant syndrome, the authors examined the association between neuroleptic malignant syndrome and polymorphisms of the 5-HT1A and 5-HT2A receptor genes.MethodThe authors examined the frequencies of gene polymorphisms in the 5-HT1A (Arg219Leu) and 5-HT2A (Thr25Asn and His452Tyr) receptor genes in 29 patients previously diagnosed with neuroleptic malignant syndrome, 94 neuroleptic-treated patients with schizophrenia who had no history of neuroleptic malignant syndrome, and 94 healthy comparison subjects. Polymerase chain reaction and restriction fragment length polymorphism analyses were used to screen gene mutations.ResultsNo polymorphic allele was detected in the patients who had experienced the neuroleptic malignant syndrome.ConclusionsThe authors cannot conclude that polymorphisms in the 5-HT1A and 5HT2A receptor genes are factors determining susceptibility to the neuroleptic malignant syndrome.

24 keywords...

hide…